Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy

20 Apr 2016

Abstract excerpt

// Jiang-Jiang Qin 1, 2, * , Wei Wang 1, 2, * , Sushanta Sarkar 1 , Sukesh Voruganti 1 , Rajesh Agarwal 3, 4 , Ruiwen Zhang 1, 2 1 Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA 2 Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA 3 Department of Pharmaceutical Sciences,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to HIV/AIDS drug development and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27105525
DOI: 10.18632/oncotarget.8873

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapyPMID 27105525Read ↗

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapASemantic proximity Read ↗

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and AndrogenSemantic proximity Read ↗

Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validationSemantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

UM171 suppresses breast cancer progression by inducing KLF2Semantic proximity Read ↗

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsSemantic proximity Read ↗

Explore the Potential Mechanism of Bufadienolides-Like Chemicals on Breast Cancer through Bioinformatics AnalysisSemantic proximity Read ↗

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastomaSemantic proximity Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicineSemantic proximity Read ↗

MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53Semantic proximity Read ↗

Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent ApoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.